ASP Isotopes

ASP Isotopes Financing Cash Flow

The Net Financing Cash Flow of ASP Isotopes (ASPI) as of Nov 18, 2026 is 350.80 M USD. In the previous year, Net Financing Cash Flow was 82.53 M USD — a change of 325.04% (higher).

Financing Cash Flow

350.80 MUSD

YoY

325.04%

Last updated:

Net Financing Cash Flow of ASP Isotopes is 2025 350.80 M USD. Net Financing Cash Flow of ASP Isotopes was 2024 82.53 M USD. It decreases by 325.04% higher compared to the previous year.

The ASP Isotopes Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2021
6.50 M USD
Jan 1, 2022
6.64 M USD
Jan 1, 2023
13.39 M USD
Jan 1, 2024
82.53 M USD
Jan 1, 2025
350.80 M USD
The ASP Isotopes Financing Cash Flow history
YEARFinancing Cash FlowYoY
350.80 MUSD+325.04%
82.53 MUSD+516.59%
13.39 MUSD+101.56%
6.64 MUSD+2.16%
6.50 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ASP Isotopes Stock analysis

What does ASP Isotopes do? ASP Isotopes, Inc. generates revenue through the development and commercialization of enriched isotopes using its Aerodynamic Separation Process (ASP technology). The company focuses on producing Carbon-14 (C-14), Molybdenum-100 (Mo-100), and Silicon-28 (Si-28) for specialized markets, with plans to expand into Uranium-235 (U-235) for the nuclear energy sector. Its subsidiaries, ASP Isotopes Guernsey Limited and Enriched Energy LLC, handle high-value isotope production and uranium development, respectively. The company licenses ASP technology from Klydon Proprietary Ltd for all isotope-related activities. The target customers for C-14, Mo-100, and Si-28 are highly specialized end markets requiring low-volume, high-value isotopes. Enriched Energy LLC specifically targets the nuclear energy market with uranium products. ASP Isotopes Guernsey Limited focuses on niche applications where isotope enrichment is critical, such as medical and industrial uses. The company’s revenue model relies on the sale of these enriched isotope products to specialized industries rather than mass-market consumers. ASP Isotopes, Inc. operates under a pre-commercial stage, meaning it is still developing its production capabilities and has not yet achieved full-scale commercialization. The company’s initial revenue streams will come from the sale of C-14, Mo-100, and Si-28, with future expansion into U-235 expected to diversify its product portfolio. The Aerodynamic Separation Process (ASP technology) is central to its business model, enabling the enrichment of natural isotopes into higher concentration products for specialized applications. ASP Isotopes is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ASP Isotopes stock

Net Financing Cash Flow of ASP Isotopes is 350.80 M USD in 2025.

Net Financing Cash Flow of ASP Isotopes changed from 82.53 M USD to 350.80 M USD, representing a 325.04% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow ASP Isotopes since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's ASP Isotopes historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — ASP Isotopes

All Key Metrics — ASP Isotopes